Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.53) by 6.19 percent. This is a 1.96 percent increase over losses of $(0.51) per share from the same period last year.